Globally renowned US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222). This is 1st time ever that an antibiotic has been granted a susceptible breakpoint of as high as 64 mg/L for all the three families of Gram negative pathogens; Enterobacterales, Pseudomonas and Acinetobacter.
2 Likes
I also loved this one.
WCK 5222 has been used successfully for a US patient!
Cleared out a nasty infection of metallo-β-lactamase-harbouring P aeruginosa in a young cancer patient, who was administered the drug on compassionate grounds, since there were no other treatment options left. 4 weeks, all clear, and well tolerated.
Feel proud that an Indian company has innovated like this.
Disclosure: Invested from lower levels, this is one of my investments âfrom the heartâ (though I know one should never do this, whatâs the fun if you donât listen to your heart?)
11 Likes